Latterell Venture Partners
Venture capitalSan Ramon · Seed–Series A · 6 people tracked
Investment thesis
Latterell Venture Partners backs early-stage healthcare companies developing innovative technologies addressing large markets, led by passionate entrepreneurs. The firm combines venture capital, entrepreneurial, technical, clinical, and collaborative expertise to help founders build successful startups. LVP aims to assemble a portfolio of leading biotechnology and medical device companies that generate strong returns for its limited partners while delivering major new disease treatments benefiting patients worldwide.
Source: firm website, verified Aug 3, 2026.
Team · 6 people
from the firm's website & public directoriesWhat they invest in
from 5 of 33 portfolio companiesBiotech ×4Healthtech ×2Medical Devices ×2Hardware ×1
HQs:United States×4
Investments · 33 tracked
founders shown can be your intro pathPulmonx develops the Zephyr Valve, a bronchoscopic medical device for treating severe COPD and emphysema without surgery.
HealthtechMedical DevicesSan Jose, US
GLENDON E. FRENCH(Executive Officer, Director)DANA G. MEAD, JR(Director)STEPHEN SALMON(Director)RODNEY PERKINS, M.D.(Director)OERN STUGE(Director)MICHAEL MATLY(Director)
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Liam Ratcliffe(Director)Ashish Khanna(Secretary & Chief Business Officer)Terry P. Gould(Director)Wilbur H. Gantz III(Director)
Cancer pharmaceutical company targeting PI3 Kinase; acquired by Gilead for up to $600M.
Developed pharmaceuticals for B-cell cancers and immune diseases; acquired by MedImmune for up to $175M.
Developed a bio-erodable femoral closure device; acquired by Johnson & Johnson for up to $90M.
Specialty pharmaceutical company developing products for GI applications; IPO'd September 2013 (EVOK).
Evoke Pharma is a specialty pharmaceutical company (NASDAQ: EVOK) developing treatments for patients with gastrointestinal diseases, with a focus on diabetic gastroparesis.
BiotechHealthtech
Developed biotech research instruments for measuring molecular binding; acquired by Pall Corporation for $159M.
Developed lightweight portable oxygen concentrators; acquired by ResMed.
Commercializing rapid DNA analysis technology for forensics; acquired by Thermo Fisher Scientific in 2018.
IntegenX (now part of Thermo Fisher Scientific) offers the Applied Biosystems RapidHIT ID System, an automated forensic DNA analysis instrument that generates STR DNA profiles in about 90 minutes with minimal hands-on time.
BiotechHardwareMedical Devices
Specialty pharma treating Eosinophilic Esophagitis; acquired by Shire for up to $245M in 2015.
Developed next-generation depression pharmaceuticals; acquired in 2015 for $560M upfront plus milestones.
Developing cancer therapeutics targeting cancer precursor cells; IPO'd July 2013 (OMED).
Mereo BioPharma develops therapies for rare genetic diseases, including osteogenesis imperfecta and alpha-1 antitrypsin deficiency-associated lung disease, operating with a capital-efficient model through strategic partnerships.
Biotech
Developed an atherectomy device for peripheral artery disease; acquired by Medrad (Bayer) for $125M.
Mountain View, US
James Woody(Director)Grace Colon(Director)Alan Jacobs(Executive Officer, Director)Rodney Markin(Director)Jennifer Jacobs(Executive Officer, Director)John Friedman(Director)
Developed cancer therapeutics targeting the proteasome; acquired by Onyx Pharmaceuticals for up to $851M.
Developed a percutaneous device to re-open chronically occluded vessels; acquired by Boston Scientific.
Developing cancer therapeutics based on apoptosis research; IPO'd December 2013.
Developed a glaucoma treatment device reducing intra-ocular pressure; acquired by Alcon/Novartis for up to $740M.
Developing oncology therapeutics for viral-induced tumors; went public February 2021 (VIRX).
Exits · 12
IPOs and acquisitions across the tracked portfolioPulmonx Corp.NASDAQ: LUNGCalistogaacq. by GileadCellective Therapeuticsacq. by MedImmuneEnsure Medicalacq. by Johnson & JohnsonForteBioacq. by PallInova Labsacq. by ResMedIntegenXacq. by Thermo Fisher ScientificMeritageacq. by ShirePathwayacq. by MedradProteolixacq. by Onyx PharmaceuticalsRevascular Therapeuticsacq. by Boston ScientificTranscendacq. by Alcon
Portfolio news
latest coverage across their companiesPulmonx Corp. · defenseworld.net · Jul 19, 2026
Frequently asked questions
- What stage does Latterell Venture Partners invest at?
- Latterell Venture Partners invests at the Seed, Series A stages.
- What is Latterell Venture Partners's typical check size?
- Latterell Venture Partners typically writes checks of $50K – $10M.
- What sectors does Latterell Venture Partners focus on?
- Latterell Venture Partners focuses on Biotech, Digital Health, Healthtech, Medical Devices.
- Where is Latterell Venture Partners located?
- Latterell Venture Partners is headquartered in San Ramon, US.
- Does Latterell Venture Partners lead rounds?
- Yes, Latterell Venture Partners leads investment rounds.
Similar investors
Amadeus Capital Partners is a UK-based deep tech venture capital firm founded in 1997 that invests from seed to growth stages across artificial intelligence, health, and sustainability-focused technologies.
B Capital Group is a global venture capital firm that backs founders from early to late stage, with dedicated stage-based funds and a portfolio spanning technology, healthcare, and energy and resilience sectors.
Breyer Capital is a venture capital firm that backs high-impact entrepreneurs, making strategic investments guided by founder passion and its network of experienced investors.
DCVC (Data Collective) is a venture capital firm that backs founders building companies which apply technology to major challenges across areas such as energy, biotech, agriculture, and machine learning.
Future Positive Capital's portfolio page showcasing companies across health, climate, and deeptech sectors.